SEC Comment Letter 0000000000-25-000229 to Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284) (OLMA)
Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284)
Date: Jan. 8, 2025 · CIK: 0001750284 · Accession: 0000000000-25-000229
AI Filing Summary & Sentiment
File numbers found in text: 333-284131
Letter
January 8, 2025 Sean Bohen, M.D., Ph.D. Chief Executive Officer and President Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, California 94103 Re:Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 3, 2025 File No. 333-284131 Dear Sean Bohen M.D., Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Julia R. Boesch
Show Raw Text
January 8, 2025
Sean Bohen, M.D., Ph.D.
Chief Executive Officer and President
Olema Pharmaceuticals, Inc.
780 Brannan Street
San Francisco, California 94103
Re:Olema Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 3, 2025
File No. 333-284131
Dear Sean Bohen M.D., Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Julia R. Boesch